RESEARCH TRIANGLE PARK, N.C., December 18, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ...

Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...

The complexities of drug development for rare diseases, including small patient populations, phenotypic variability, and the high costs associated with large-scale clinical trials, have long hindered ...

Detailed price information for Simulations Plus Inc (SLP-Q) from The Globe and Mail including charting and trades.